natalizumab
biogen
['natalizumab', 'biogen']
results showed autologous hematopoietic stem cell transplantation to not be more beneficial for reducing disability progression than #natalizumab among patients with progressive #ms. #latebreaker #ectrims2022 view: 
Delivering healthcare professionals treating neurological diseases quality and relevant information to help achieve the best patient care possible. #MindMoments